房颤患者PCI后1个月与12个月双联抗栓治疗比较:OPTIMA-AF研究
OPTIMA-AF研究在日本75个中心纳入1079例接受PCI的非瓣膜性房颤患者,比较1个月双联抗栓后DOAC单药与12个月双联抗栓后DOAC单药的疗效与安全性。结果显示1个月组在12个月全因死亡或血栓栓塞复合终点上非劣效于12个月组;主要安全性终点方面,1个月组大出血或临床相关非大出血发生率显著更低。总体净临床获益支持短期双联抗栓策略。
要点
- 房颤患者PCI后1个月DOAC加P2Y12抑制剂双联抗栓后转为DOAC单药,疗效非劣效于12个月双联方案。
- 1个月双联抗栓组大出血或临床相关非大出血风险较12个月组降低约一半。
- 主要疗效终点事件率低于预期,解读疗效结论时需谨慎。
核心结论
- 在主要因慢性冠脉综合征接受PCI且采用血管内影像指导的房颤患者中,1个月双联抗栓后转为DOAC单药在12个月全因死亡或血栓栓塞复合终点上非劣效于12个月双联抗栓。
- 1个月双联抗栓组12个月大出血或临床相关非大出血发生率显著低于12个月双联抗栓组,提示总体净临床获益更优。
研究设计与样本
- 多中心、开放标签、混合非劣效与优效性随机对照试验,在日本75个中心开展。
- 房颤患者接受血管内影像指导PCI后按1:1随机分为1个月双联抗栓组(DOAC加P2Y12抑制剂)后DOAC单药组,或12个月双联抗栓后DOAC单药组。
- 主要疗效终点为12个月全因死亡或血栓栓塞事件复合终点;主要安全性终点为12个月大出血或临床相关非大出血。
- 采用固定顺序检验策略:先检验疗效非劣效,再检验安全性优效,最后检验疗效优效。
- 全分析集纳入1079例患者,其中1个月双联组542例,12个月双联组537例。
主要发现
- 中位年龄76岁(IQR 70-81);1079例中女性225例(21%),男性854例(79%);中位CHADS2评分为2(IQR 2-3)。
- 中位随访540天(IQR 517-559)。
临床怎么用
- 对于主要因慢性冠脉综合征接受PCI且使用血管内影像指导的房颤患者,可考虑术后1个月DOAC加P2Y12抑制剂双联抗栓后转为DOAC单药。
- 短期双联抗栓较12个月双联方案更有利于减少出血风险,同时未明显增加血栓栓塞或死亡事件。
局限性
- 主要疗效终点事件率低于预期,解读疗效结论时需结合固定绝对非劣效界值审慎判断。
- 研究为开放标签设计,研究者和患者知晓治疗分组,可能影响事件报告行为。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal duration of dual antithrombotic therapy after percutaneous coronary intervention (PCI) in patients with atrial fibrillation remains uncertain. We aimed to compare the efficacy and safety of 1-month versus 12-month dual antithrombotic therapy in this population. METHODS: OPTIMA-AF was an active-control, randomised, hybrid non-inferiority and superiority trial in which patients with atrial fibrillation undergoing PCI with intravascular imaging guidance were randomly assigned (1:1) to receive 1-month dual antithrombotic therapy (direct oral anticoagulant [DOAC] plus P2Y12 inhibitor) followed by DOAC monotherapy or 12-month dual therapy followed by DOAC monotherapy, across 75 sites in Japan. Eligible patients were aged 20 years or older with non-valvular atrial fibrillation, a CHADS2 score of 1 or higher, undergoing PCI for native coronary lesions for chronic coronary syndrome or unstable angina, with planned post-PCI treatment with a DOAC. Randomisation used web-based central allocation stratified by trial centre. Investigators and patients were unmasked; clinical events were adjudicated by an independent committee masked to treatment. The primary efficacy endpoint was a composite of all-cause death or thromboembolic events at 12 months; the primary safety endpoint was major or clinically relevant non-major bleeding at 12 months. The trial used a fixed-sequence testing strategy of non-inferiority for efficacy, superiority for safety, and superiority for efficacy. Analyses used the full analysis set including all patients who underwent PCI, were randomly assigned to treatment, received at least one dose of study drugs, and met prespecified analysis-set criteria. This trial is registered with the Japan Registry of Clinical Trials (jRCTs051190053), and is complete. FINDINGS: From Oct 7, 2019, to Sept 3, 2024, 1101 patients were assessed for eligibility; 1088 were randomly assigned to treatment and 1079 were included in the full analysis set (1-month dual therapy n=542; 12-month dual therapy n=537). Median age was 76 years (IQR 70-81). 225 (21%) of 1079 patients were female and 854 (79%) were male. Median CHADS2 score was 2 (IQR 2-3). Median follow-up was 540 days (IQR 517-559). The primary efficacy endpoint occurred in 29 patients in the 1-month dual therapy group and 23 patients in the 12-month dual therapy group (Kaplan-Meier estimate 5·4% vs 4·3%; absolute difference 1·1 percentage points [95% CI -1·5 to 3·6]; hazard ratio [HR] 1·25 [95% CI 0·73-2·17]). The primary safety endpoint occurred in 24 patients versus 47 patients (Kaplan-Meier estimate 4·5% vs 8·8%; absolute difference -4·4 percentage points [95% CI -7·3 to -1·4]; HR 0·50 [95% CI 0·30-0·81]; p=0·0041 for superiority). INTERPRETATION: Among patients with atrial fibrillation and predominantly chronic coronary syndrome undergoing PCI with intravascular imaging guidance, 1-month dual antithrombotic therapy followed by DOAC monotherapy was non-inferior to 12-month therapy for death or thromboembolic events and reduced major or clinically relevant non-major bleeding at 12 months, suggesting an overall favourable net clinical profile. Efficacy findings should be interpreted with appropriate caution in light of the lower-than-anticipated event rates and fixed absolute non-inferiority margin. FUNDING: Abbott Medical Japan. TRANSLATIONS: For the Japanese translation of the abstract see Supplementary Materials section.
引用
- Sotomi, Kozuma, Higuchi, et al. 1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial. Lancet. 2026. PMID: 42456692. doi:10.1016/S0140-6736(26)00665-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。